At Abbott, we adapt quickly to changes in the world around us, harnessing leading-edge science and technology to deliver the best possible solutions for some of the world’s most important health challenges. Medical devices, like the Abbott AVEIR™ VR Leadless Pacemaker, use the most advanced technologies to keep hearts beating more regularly.
.png)
The average battery longevity among Leadless II phase 2 IDE patients at 1 year follow-up is estimated to be 17.6 years
48% of the study patients have an estimated battery longevity of over 20 years.
AVEIR VR Leadless Pacemaker can measure R-waves, impedance, and an initial capture threshold before fixation by simply touching the electrode to the endocardial tissue.1,4 AVEIR VR Leadless Pacemaker is engaged with a rotational motion into the endocardium.
AVEIR VR Leadless Pacemaker mapping capability is designed to help reduce the number of repositioning attempts.1,4
83.2% of patients had successful implants with no repositioning attempts4
96.4% of patients had successful implants in 1 or less repositioning attempts4
Should new pacing indications present, the software for AVEIR VR Ventricular LP is designed to pair with AVEIR AR Atrial LP, allowing the devices to upgrade to an AVEIR DR Dual Chamber Leadless Pacemaker System.1**
AVEIR VR LP is MR Conditional for full body scans using a 1.5T or 3T field strength MRI scanner.***
References
* Battery longevity estimates based on projections derived from published technical specifications and the ISO standard settings
** AVEIR AR Atrial leadless pacemaker system and AVEIR DR dual chamber leadless pacemaker system are commercially approved for use only in the USA market at this time. The AVEIR AR and DR systems are currently under review and pending CE mark.
***For additional information about specific MR Conditional, including warnings, precautions, adverse conditions to MRI scanning and potential adverse events, please refer to the MRI-Ready Leadless Systems Manual at medical.abbott/manuals or check our MRI Ready resources at cardiovascular.abbott/mriready
1. AVEIR™ VR Leadless Pacemaker and Delivery Catheter IFU. ARTEN600186860
2. Reddy, VY, et al. Worldwide Experience with Leadless Pacemaker Retrievals at 9 years. Presented at 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session; Nov 18-20, 2022; Singapore.
3. Micra‡ VR IFU M991010A001 REV. B
4. Reddy VY, Exner D, et al. 1-Year Outcomes of a Leadless Ventricular Pacemaker: The LEADLESS II (Phase 2) Trial. JACC: Clinical Electrophysiology 2023, DOI: 10.1016/j.jacep.2023.01.031.
Additional References
a. Sattar et al. Complications of leadless vs conventional (lead) artificial pacemakers - a retrospective review. Journal of Community Hospital Internal Medicine Perspectives Vol. 10,4 328-333. 2 Aug. 2020, doi:10.1080/20009666.2020.178690.
b. Reddy VY, Cantillon DJ, John IP . San Francisco, CA: 6 May 2016. A comparative study of acute and mid-term complications of leadless vs transvenous pacemakers. Late-Breaking Clinical Trials II. Presented at Heart Rhythm Society 2016; pp. 02–04. Abstract LBCT.
MAT-2310327 v1.0
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?
MAT-2305078 v1.0
